

Appl. No. 10/587,410
Reply to Office Action mailed October 9, 2008

R E M A R K S

Information Disclosure Statement Dated August 30, 2006

A copy of the Form PTO/SB/08A dated August 30, 2006 was returned with the previous Office Action mailed February 24, 2008, with the Examiner's initials next to each cited publication, except for JP 2003-500401. On said copy of the Form PTO/SB/08A dated August 30, 2006, a line was drawn through JP 2003-500401, and the following handwritten notation was made: "Not translated." On said Form PTO/SB/08A dated August 30, 2006, it was stated that an English-language abstract of JP 2003-500401 was provided and that USP 6,380,214 is a related family member of JP 2003-500401.

In view of the above, the Examiner is respectfully requested to return another copy of Sheet 1 of said Form PTO/SB/08A dated August 30, 2006, with the Examiner's initials next to all the cited publications, including JP 20030-500401.

Claim Amendments

Claims 1, 2 and 15 were canceled.

Appl. No. 10/587,410
Reply to Office Action mailed October 9, 2008

Claim 3 was amended into independent form by inclusion of the formula (I) recited in claim 1.

Claims 3 and 4 were amended to recite that R¹ is phenyl. This amendment is consistent with applicants' election in reply to the Restriction Requirement (see page 2, lines 4 to 7 of the October 9, 2008 Office Action).

Editorial revisions were made to claims 3 to 9.

Claims 5, 7, 9, 11 and 16 to 27 were amended to change claim dependencies.

Claim 10 was amended to delete compounds.

Claim 14 was amended to include features of claim 15.

With respect of Rule 116, entry of the claim amendments is respectfully requested, since the amendments generally involve features that were set forth in the claims prior to the final rejection. The claim amendments also serve to place allowable subject matter into allowable format (see the first paragraph on page 6 of the October 9, 2008 Office Action).

Rejections Under 35 USC 112, First and Second Paragraphs

Claims 14 and 15 were rejected under 35 USC 112, first and second paragraphs, for the reasons set forth beginning at the

Appl. No. 10/587,410
Reply to Office Action mailed October 9, 2008

middle of page 2 and continuing to the bottom of page of the October 9, 2008 Office Action.

Claim 14 was amended hereinabove to replace the terminology of "a disease in which angiogenesis or vascular hyperpermeability is involved" with the specific disease set forth in claim 15. In this regard, attention is directed to the test data on pages 279 to 289 of the specification, which show anticancer activity, anti-arthritis activity and choroidal neovascularization inhibition activity for compounds according to the present invention.


Withdrawal of all the rejections under 35 USC 112 is thus respectfully requested.

Reconsideration is requested. Allowance is solicited.

If the Examiner has any comments, questions, objections or recommendations, the Examiner is invited to telephone the undersigned at the telephone number given below for prompt action.

Frishauf, Holtz, Goodman
& Chick, P.C.
220 Fifth Avenue, 16th Fl.
New York, NY 10001-7708
Tel. No. (212) 319-4900
Fax No.: (212) 319-5101
E-Mail Address: BARTH@FHGC-LAW.COM
RSB/ddf

Respectfully submitted,



Richard S. Barth
Reg. No. 28,180